First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies ProgramSupports development of countermeasures against orthopoxviruses, a high-priority biological threat family that...

MOFFITT CANCER CENTER LAUNCHES RADIOPHARMA PROGRAM TO ACCELERATE RESEARCH, CLINICAL TRANSLATION AND MANUFACTURING OF NEXT GENERATION CANCER TREATMENTNew interdisciplinary program will bring together clinical, research and operational expertise to position...

CONTEMPORARY HEALTH SYSTEMS Announces the USPTO has issued a Patent for its transformative Biomarker Assessment of Olfactory and Gustatory Functioning for Detection and Monitoring of multiple neurological diseases and downstream...

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-EverFDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen StorageDisease Type Ia (GSDIa)August 19, 2026GENGLYCOS is the first gene...

Wellvii™ BP Go Achieves FDA Clearance as the Most Compact and Portable Non-Invasive Blood Pressure Finger Cuff Eliminating the Need for the Arm CuffPALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Wellvii today announced...

May 28, 2026 | Press ReleasesCollaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic’s C1 Platform Capabilities for Fast, Scalable Biologic ProductionJUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE)...

SARASOTA, Fla., April 9, 2026 /PRNewswire/ -- Ziptek, an emerging international medical device innovator, today announced significant clinical and commercial momentum for its revolutionary ZipE® Biolock™ technology—a first-of-its-kind, resorbable tissue...

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)Mar 4, 2026 | Press ReleasesJUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) —...

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development MilestoneJUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) — Dyadic...

February 24, 2026 08:30 ET | Source: Cadrenal Therapeutics Inc.Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no...